Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial

医学 苯达莫司汀 美罗华 套细胞淋巴瘤 长春新碱 内科学 切碎 强的松 临床终点 外科 胃肠病学 环磷酰胺 淋巴瘤 化疗 随机对照试验
作者
Mathias Rummel,N. Niederle,Georg Maschmeyer,Gamal-Andre Banat,Ulrich von Grünhagen,Christoph Losem,Dorothea Kofahl-Krause,Gerhard Heil,Manfred Welslau,Christina Balser,Ulrich Kaiser,Eckhart Weidmann,Heinz Dürk,Harald Balló,Martina Stauch,Fritz Roller,Juergen Barth,Dieter Hoelzer,Axel Hinke,Wolfram Brugger
出处
期刊:The Lancet [Elsevier]
卷期号:381 (9873): 1203-1210 被引量:1272
标识
DOI:10.1016/s0140-6736(12)61763-2
摘要

Background Rituximab plus chemotherapy, most often CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone), is the first-line standard of care for patients with advanced indolent lymphoma, and for elderly patients with mantle-cell lymphoma. Bendamustine plus rituximab is effective for relapsed or refractory disease. We compared bendamustine plus rituximab with CHOP plus rituximab (R-CHOP) as first-line treatment for patients with indolent and mantle-cell lymphomas. Methods We did a prospective, multicentre, randomised, open-label, non-inferiority trial at 81 centres in Germany between Sept 1, 2003, and Aug 31, 2008. Patients aged 18 years or older with a WHO performance status of 2 or less were eligible if they had newly diagnosed stage III or IV indolent or mantle-cell lymphoma. Patients were stratified by histological lymphoma subtype, then randomly assigned according to a prespecified randomisation list to receive either intravenous bendamustine (90 mg/m2 on days 1 and 2 of a 4-week cycle) or CHOP (cycles every 3 weeks of cyclophosphamide 750 mg/m2, doxorubicin 50 mg/m2, and vincristine 1·4 mg/m2 on day 1, and prednisone 100 mg/day for 5 days) for a maximum of six cycles. Patients in both groups received rituximab 375 mg/m2 on day 1 of each cycle. Patients and treating physicians were not masked to treatment allocation. The primary endpoint was progression-free survival, with a non-inferiority margin of 10%. Analysis was per protocol. This study is registered with ClinicalTrials.gov, number NCT00991211, and the Federal Institute for Drugs and Medical Devices of Germany, BfArM 4021335. Findings 274 patients were assigned to bendamustine plus rituximab (261 assessed) and 275 to R-CHOP (253 assessed). At median follow-up of 45 months (IQR 25–57), median progression-free survival was significantly longer in the bendamustine plus rituximab group than in the R-CHOP group (69·5 months [26·1 to not yet reached] vs 31·2 months [15·2–65·7]; hazard ratio 0·58, 95% CI 0·44–0·74; p<0·0001). Bendamustine plus rituximab was better tolerated than R-CHOP, with lower rates of alopecia (0 patients vs 245 (100%) of 245 patients who recieved ≥3 cycles; p<0·0001), haematological toxicity (77 [30%] vs 173 [68%]; p<0·0001), infections (96 [37%] vs 127 [50%]); p=0·0025), peripheral neuropathy (18 [7%] vs 73 [29%]; p<0·0001), and stomatitis (16 [6%] vs 47 [19%]; p<0·0001). Erythematous skin reactions were more common in patients in the bendamustine plus rituximab group than in those in the R-CHOP group (42 [16%] vs 23 [9%]; p=0·024). Interpretation In patients with previously untreated indolent lymphoma, bendamustine plus rituximab can be considered as a preferred first-line treatment approach to R-CHOP because of increased progression-free survival and fewer toxic effects. Funding Roche Pharma AG, Ribosepharm/Mundipharma GmbH.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
1秒前
sun发布了新的文献求助10
5秒前
zhanks发布了新的文献求助10
6秒前
jiejie完成签到,获得积分10
11秒前
sun完成签到,获得积分10
12秒前
15秒前
嚣张的豆豆完成签到,获得积分10
15秒前
繁荣的念双完成签到,获得积分10
16秒前
共享精神应助米九采纳,获得10
16秒前
小蘑菇应助小羊要加油采纳,获得10
17秒前
完美世界应助研友_LaV1xn采纳,获得10
18秒前
leijh123完成签到,获得积分20
19秒前
xv完成签到,获得积分10
19秒前
CGBY完成签到 ,获得积分10
20秒前
科研通AI2S应助科研通管家采纳,获得30
22秒前
orixero应助科研通管家采纳,获得10
22秒前
wanci应助科研通管家采纳,获得10
23秒前
Byby应助柚屿采纳,获得30
23秒前
23秒前
研友_VZG7GZ应助科研通管家采纳,获得10
23秒前
香蕉觅云应助科研通管家采纳,获得10
23秒前
科研通AI2S应助科研通管家采纳,获得10
23秒前
23秒前
SciGPT应助科研通管家采纳,获得10
23秒前
Mobius完成签到,获得积分10
23秒前
24秒前
26秒前
训仔完成签到,获得积分10
26秒前
27秒前
29秒前
31秒前
赘婿应助dudu采纳,获得10
31秒前
31秒前
科目三应助AmyHu采纳,获得10
32秒前
江上钓太公完成签到,获得积分10
34秒前
斯文败类应助哈哈哈哈采纳,获得10
35秒前
niumi190发布了新的文献求助20
36秒前
礽粥粥发布了新的文献求助10
36秒前
瘦瘦的睫毛膏完成签到,获得积分10
37秒前
38秒前
高分求助中
Sustainability in Tides Chemistry 1500
TM 5-855-1(Fundamentals of protective design for conventional weapons) 1000
CLSI EP47 Evaluation of Reagent Carryover Effects on Test Results, 1st Edition 800
Threaded Harmony: A Sustainable Approach to Fashion 799
Livre et militantisme : La Cité éditeur 1958-1967 500
Retention of title in secured transactions law from a creditor's perspective: A comparative analysis of selected (non-)functional approaches 500
"Sixth plenary session of the Eighth Central Committee of the Communist Party of China" 400
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 基因 遗传学 催化作用 物理化学 免疫学 量子力学 细胞生物学
热门帖子
关注 科研通微信公众号,转发送积分 3055401
求助须知:如何正确求助?哪些是违规求助? 2712227
关于积分的说明 7430195
捐赠科研通 2357037
什么是DOI,文献DOI怎么找? 1248528
科研通“疑难数据库(出版商)”最低求助积分说明 606737
版权声明 596093